Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BCCs in Gorlin Syndrome Patients”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Testing effectiveness (Phase 2)Ended earlyNCT04155190
What this trial is testing

Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

Who this might be right for
Recurrent Basal Cell Carcinoma
Sol-Gel Technologies, Ltd. 47
Testing effectiveness (Phase 2)Study completedNCT04893486
What this trial is testing

CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

Who this might be right for
BCCs in Gorlin Syndrome Patients
Palvella Therapeutics, Inc. 73
Testing effectiveness (Phase 2)Study completedNCT01350115
What this trial is testing

Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Who this might be right for
Basal Cell CarcinomaGorlin SyndromeNevoid Basal Cell Carcinoma Syndrome
Novartis Pharmaceuticals 10
Testing effectiveness (Phase 2)Study completedNCT00961896
What this trial is testing

A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients

Who this might be right for
Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients
Novartis Pharmaceuticals 18